22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent deci...
Read More >
In this second edition of October HorrorFest 2020 celebration we consider the first Hammer film vers...
Read More >
On Friday, November 22, 2019, State District Judge Peter Sakai granted a temporary injunction enjoin...
Read More >
Pillsbury continues to track the impact on construction projects of COVID-19-related orders and guid...
Read More >
Introduction - Owners and contractors involved in large-scale energy and manufacturing projects fac...
Read More >
This alert is the fourth installment in our series on Illinois’ new anti-harassment legislation, SB...
Read More >